Study shows novel sa-mrna vaccines offer robust, broad, enduring protection against covid-19 variants

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the results of a phase 1/2 study showing that a booster dose of a novel, self-amplifying messenger rna (sa-mrna) vaccine against covid-19 induces a robust, broadly cross-reactive, and durable imm.
ARCT Ratings Summary
ARCT Quant Ranking